

BioFacilities, June 2020

Covance opened its new Central Laboratory and Bioanalysis Lab genomics facility in Indianapolis, Indiana, USA. *Source: Contract Pharma, Feb. 28, 2020*

FUJIFILM Diosynth Biotechnologies U.S.A., Inc. is constructing a 31,000 sq. ft. expansion of mammalian cell culture capacity at its facility in Morrisville, North Carolina, USA. This will increase mammalian cell culture capacity by about 25% and microbial fermentation capacity by 50%. *Source: GMP News, Feb. 27, 2020*

Audentes Therapeutics (Astellas Pharma) is constructing a USD \$109 MIL, 135,000 sq. ft. "large scale" gene therapy facility in Sanford, North Carolina, USA. *Source: Biopharm Intl., Feb. 19, 2020*

Novo Nordisk is investing USD \$116 MIL to upgrade and expand insulin products manufacturing at its facility in Kalundberg, Denmark, which is already the world's largest insulin manufacturing facility, providing more than 50% of the world's supply of insulin. *Source: NS Healthcare, Feb. 10, 2020*

Hitachi Chemical Advanced Therapeutics Solutions (HCATS) (Hitachi Chemical) opened a cellular and gene therapies CMO manufacturing facility in Allendale, New Jersey, USA, with 6 cleanroom suites and eventually 500 staff. *Source: Pharmaceutical Technology, Feb. 6, 2020*

Viniti, a company spun-off from GE Ventures (now Cytiva), providing logistics support for cellular and gene therapies, received funding from co.'s including Cardinal Health, Novartis Pharma AG and Kite, a division of Gilead Sciences, Inc., to expand its facilities in Europe and Asia. *Source: Press release, Feb. 5, 2020*

UCB is constructing a USD \$333 MIL facility in Braine l'Alleud, Belgium, with 150 staff for commercial manufacture of its monoclonal antibodies. *Source: GMP News, Jan. 31, 2020*

Merck KGaA (Germany) will construct a USD \$275 MIL bioprocessing facility in Corsier-sur-Vevey, Switzerland, for clinical supplies manufacturing, starting with 3 x 2,000 L bioreactor-anchored process lines. *Source: BioPharma-reporter.com, Jan. 30, 2020*

AbbVie (formerly Allergan) opened a new USD \$176 MIL BOTOX (botulinum toxin) manufacturing facility in Westport, Ireland, adding 63 jobs. *Source: FiercePharma, Jan. 28, 2020*

The **Center for Breakthrough Medicines**, a new USD \$1.1 BIL gene therapy CMO facility, is being constructed by MLP Ventures and Deerfield Management on the site of a former GlaxoSmithKline (GSK) facility in King of Prussia, Pennsylvania, USA, now owned by the former Chairman of Paragon (sold to Catalent for USD \$1.2 BIL). *Source: FiercePharma, Jan. 23, 2020*

Eli Lilly & Co. is investing USD \$470 MIL to expand its insulins manufacturing facilities in Indianapolis, IN, including adding 460 jobs. *Source: PharmaNewsIntelligence, Jan. 22, 2020*

Just-Evotec Biologics (Seattle, WA) received USD \$15 MIL from Merck & Co. to provide bioprocessing manufacturing capacity at its Redmond, Washington, USA, facility using its modular J.POD cleanrooms. *Source: Cleanroom Technology, Jan 22, 2020*

Yposkesi S.A. (France), a gene therapy CMO, is adding about 2,000 L capacity for adeno-associated virus (AAV) and lentivirus (LV) large scale manufacturing, bringing capacity up to about 2,000 L. *Source: BioPharma-reporter.com, Jan. 14, 2020*

Korea is investing USD >.\$500 MIL to construct a 120,000 L commercial-scale bioprocessing facility in Wuhan, China, with this to be the largest biopharmaceutical manufacturing facility in China. *BioSpectrum Asia Edition, Jan. 14, 2020*

AGC Biologics completed its expanded plasmid DNA, gene therapy CMO facilities in Heidelberg, Germany, and can scale plasmid GMP manufacture to 1,000 L. *Source: Manufacturing Chemist, Jan. 2, 2020*

Amgen leased 240,000 sq. ft. in S. San Francisco, California, USA, for R&D facilities. *Source: Pharma's Almanac, Dec. 10, 2019*

Other News

Thermo Fisher is acquiring Qiagen (The Netherlands), a “molecular diagnostics” company, for USD \$11.5 BIL
Source: BioPharma Intl., March 5, 2020

The U.S. pharmaceutical industry is now reported by PhRMA to be the largest U.S. employer of R&D workers, employing 146,000 in 2107. *Source: BioPharma-reporter.com, Feb. 17, 2020*

GlaxoSmithKline (GSK) is laying-off 935 from its multiple vaccine R&D and commercial manufacturing facilities in Belgium, while increasing onsite automation. [Note, this was shortly before such companies started announcing Covid-19 vaccine-related expansions]. *Source: BioPharma-reporter.com, Feb. 11, 2020*

Catalent acquired MaSTherCell, a cellular/gene therapy CMO for USD \$330 MIL, including its ~85,000 sq. ft. of facilities in Belgium and Texas. This is in addition to Catalent recently acquiring Paragon Bioservices (Baltimore, Maryland, USA) for USD \$1.2 BIL. *Source: Catalent press release, Feb. 10, 2020*

Aridis Pharmaceuticals (San Jose, CA) reports they developed a cell line for manufacture of monoclonal antibodies in ½ the time. *Source: BioPharma-reporter.com, Feb. 5, 2020*

WuXi STA opened a new oligonucleotides and peptides conjugates manufacturing plant in Changzhou, China, with 1.5 Million L of (chemical) reactor capacity. *Source: PRNewswire, Jan 2, 2020*

Cytiva (former GE) and the Guangzhou Development District Investment Promotion Bureau (GDD; Guangzhou, China) agreed to develop the Guangzhou Bioprocess Academy to provide training in bioprocessing, with classes starting this Fall. *Source: BioPharm Intl., Dec. 5, 2019*